Evidence map›Paper›PMID 33421604›Full record

ArticleJournal of ethnopharmacology2021

Botanical formulation, TADIOS, alleviates lipopolysaccharide (LPS)-Induced acute lung injury in mice via modulation of the Nrf2-HO-1 signaling pathway.

Wonwoo Lee, Chang Hyung Lee, Jungkyu Lee, Yoonseon Jeong, Jong-Hyung Park, In-Jeong Nam, Doo Suk Lee, Hyun Myung Lee, Jaehyun Lee, Nayoung Yun and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of ethnopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Journal of microbiology and biotechnology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Wonwoo LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: wwlee@helixmith.com.
Chang Hyung LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: chlee@helixmith.com.
Jungkyu LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: jklee@helixmith.com.
Yoonseon JeongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: ysjeong@helixmith.com.
Jong-Hyung ParkR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: vetjh@naver.com.
In-Jeong NamR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: ijnam@helixmith.com.
Doo Suk LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: dslee@helixmith.com.
Hyun Myung LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: hmlee2@helixmith.com.
Jaehyun LeeR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: jaehyunlee@helixmith.com.
Nayoung YunR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: nyyun@helixmith.com.
Jisun SongR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: Jisun.Song@helixmith.com.
Sooyeon ChoiR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: Sooyeon.Choi@helixmith.com.
Sunyoung KimR&D Center for Innovative Medicines, Helixmith Co., Ltd., Seoul, 07794, South Korea. Electronic address: sk@helixmith.com.
Helixmith (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ethnopharmacological relevanceTADIOS is an herbal formulation prepared from a mixture of Taraxacum officinale (L.) Weber ex F.H.Wigg, Dioscorea batatas Decaisne and Schizonepeta tenuifolia (Benth.) Briquet. These plants have traditionally been used in Asia to treat a variety of respiratory diseases. A bulk of literature on traditional Korean medicine describe their activities and functions for respiratory problems. Therefore, we hypothesized that the combination of these plants might be effective in alleviating respiratory symptoms. AIM OF THE STUDY: In this study, we investigated whether TADIOS ameliorates LPS-induced acute lung injury via regulation of the Nrf2-HO-1 signaling pathway. MATERIALS AND

methodsThe LPS-induced acute lung injury mouse model was used to determine the anti-inflammatory and anti-oxidative stress effects of TADIOS. The amount of marker compounds contained in TADIOS was quantified using high-performance liquid chromatography (HPLC) analysis. The protein level of pro-inflammatory cytokines in culture supernatant was measured by ELISA. Changes in the RNA level of pro-inflammatory cytokines in mice lungs and RAW264.7 cells were measured by quantitative RT-PCR. The relative amounts of reactive oxygen species (ROS) were measured by DCF-DA assay. Western blot analysis was used to evaluate expression of cellular proteins. Effects of TADIOS on antioxidant responsive elements (AREs) were determined by luciferase assay. The severity of acute lung injury was evaluated by Hematoxylin & Eosin (H&E) staining. To test the effects of TADIOS on LPS-induced oxidative stress, myeloperoxidase (MPO) activity and the total antioxidant capacity were measured.

resultsTADIOS was prepared by extraction of a blend of these three plants by ethanol, and quality control was performed through quantification of marker compounds by HPLC and measurement of bioactivities using cell-based bioassays. In the murine macrophage cell line RAW264.7, TADIOS effectively suppressed the production of pro-inflammatory cytokines such as IL-6 and IL-1β, and also ROS induced by LPS. When RAW264.7 cells were transfected with a luciferase reporter plasmid containing nucleotide sequences for AREs, TADIOS treatment increased the level of relative luciferase units in a dose-dependent manner. In the LPS-induced acute lung injury mouse model, orally administered TADIOS alleviated lung damage and neutrophil infiltration induced by LPS. Consistent with the in vitro data, treatment with TADIOS inhibited the LPS-mediated expression of pro-inflammatory cytokines and oxidative stress, and activated the Nrf2-HO-1 axis.

conclusionOur data suggest the potential for TADIOS to be developed as a safe and effective therapeutics for the treatment of acute respiratory distress syndrome.

Indexed as

Acute Lung InjuryAnimalsAnti-Inflammatory AgentsAntioxidantsCytokinesHeme Oxygenase-1InflammationLipopolysaccharidesMaleMedicine, Korean TraditionalMembrane ProteinsMiceMice, Inbred C57BLNF-E2-Related Factor 2Oxidative StressPlant ExtractsAnti-Inflammatory AgentsAntioxidantsCytokinesHeme Oxygenase-1Hmox1 protein, mouseLipopolysaccharidesMembrane ProteinsNfe2l2 protein, mouseNF-E2-Related Factor 2Plant ExtractsReactive Oxygen SpeciesAcute respiratory distress syndromeDioscorea batatasHO-1InflammationNrf2Schizonepeta tenuifoliaTADIOSTaraxacum officinale

Identifiers

PMID33421604
PMCPMC7832766
OpenAlexW3120628298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.